Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.66 |
| ▸ | CDK2 | P24941 | 10/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 9/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.53 |
| ▸ | MGMT | P16455 | 4/20 | 0.53 |
| ▸ | PRKACA | P17612 | 2/20 | 0.52 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533603 | 0.79 | PDPK1 (0.44) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL24053 | 0.79 | PDPK1 (1.00) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL28206545 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL27891733 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL8757979 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| SCHEMBL27870406 | 0.77 | PDPK1 (0.61) | PDPK1GDACDK2DPP4MAP3K5 | |
| SCHEMBL24500763 | 0.76 | XDH (0.56) | PDPK1GDACDK2DPP4 | |
| 6-Chloroguanine SCHEMBL64059 | 0.76 | DPP4 (1.00) | PDPK1GDACDK2DPP4MAP3K5 | |
| Thioguanine SCHEMBL183648 | 0.76 | PDPK1 (0.66) | PDPK1GDACDK2DPP4MAP3K5 | |
| SCHEMBL2867588 | 0.76 | PDPK1 (0.66) | PDPK1GDACDK2DPP4MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104768964-B | Artificial nucleosides and oligonucleotides having guanidine bridges | 国立大学法人大阪大学 | 2017-03-29 | — | — | CN | claimed |
| EP-2711009-A1 | Compounds for use in treating or preventing primary and metastatic breast and prostate cancer | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2014-03-26 | — | — | EP | claimed |
| EP-2711007-A1 | 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2014-03-26 | — | — | EP | claimed |
| EP-2711008-A1 | N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2014-03-26 | — | — | EP | claimed |
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3943494-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-3153514-B1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-0174272-B1 | PROCESS FOR THE PREPARATION OF DIMETHYLMALEIC ANHYDRIDE | CIBA-GEIGY AG (CH) | 1988-08-31 | — | — | EP | disclosed |
| EP-0175641-B1 | PROCESS FOR THE PREPARATION OF DIMETHYLMALEIC ANHYDRIDE | CIBA-GEIGY AG (CH) | 1988-02-24 | — | — | EP | disclosed |
| US-4644069-A | HEATING MALEIC ACID OR ANHYDRIDE WITH AN AMIDINE OR ITS SALT | CIBA-GEIGY CORPORATION (US) | 1987-02-17 | — | — | US | disclosed |
| US-4639531-A | HETEROCYCLIC AMIDINE CATALYST | CIBA-GEIGY CORPORATION (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0175641-A1 | Process for the preparation of dimethylmaleic anhydride | CIBA-GEIGY AG (CH) | 1986-03-26 | — | — | EP | disclosed |
| EP-0174272-A1 | Process for the preparation of dimethylmaleic anhydride | CIBA-GEIGY AG (CH) | 1986-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PDPK1 18/4885GDA 273/4885CDK2 123/4885 |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PDPK1 18/4885GDA 273/4885CDK2 123/4885 |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PDPK1 19/4885GDA 1662/4885CDK2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.